Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908696 | 0.93 | NPC1 (0.52) | CHRM4KDRRAB9APOLBKMT2A | |
| SCHEMBL14006462 | 0.88 | SCD (0.56) | KDRRAB9AKMT2ANPC1MEN1 | |
| SCHEMBL4919395 | 0.88 | SCD (0.57) | HTTKCNK3POLBKMT2AMEN1 | |
| SCHEMBL14006452 | 0.85 | GSK3A (0.43) | CHRM4HTTKDRRAB9AKMT2A | |
| SCHEMBL14006470 | 0.84 | LCK (0.49) | RAB9AKMT2ANPC1MEN1TNIK | |
| SCHEMBL4916854 | 0.84 | LCK (0.54) | KCNK3KDRRAB9APOLBKMT2A | |
| SCHEMBL14006457 | 0.84 | NPC1 (0.50) | HTTKCNK3KDRRAB9APOLB | |
| SCHEMBL4914636 | 0.84 | MEN1 (0.53) | POLBKMT2AMEN1TNIKMAPT | |
| SCHEMBL14034255 | 0.84 | LCK (0.45) | CHRM4KCNK3KDRRAB9APOLB | |
| SCHEMBL14034418 | 0.83 | LCK (0.46) | KDRRAB9APOLBKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | claimed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | claimed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | CHRM4 4780/4885HTT 3334/4885KCNK3 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.